LTFS
GNRX

Ladenburg Thalmann Financial Services’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio GNRX Stock Details GNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200
Closed -$4K – 5145
2016
Q4 		$4K Buy
+200
New +$4.47K ﹤0.01% 4382

Other funds holding GNRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Ladenburg Thalmann Financial Services's GNRX Position: Q1 2017 in Review

Ladenburg Thalmann Financial Services sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q1 2017, closing a stake of 200 shares — an estimated $4K sold.

Ladenburg Thalmann Financial Services first reported a position in GNRX in Q4 2016 and held it in 1 quarter. The position peaked at $4K in Q4 2016. 4 funds tracked by Wall St. Rank hold GNRX as of Q1 2017.

  • Ladenburg Thalmann Financial Services reported no remaining VanEck Vectors Generic Drugs ETF position as of Q1 2017 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 200 VanEck Vectors Generic Drugs ETF shares in Q1 2017, an estimated $4K.
  • Ladenburg Thalmann Financial Services first reported a position in VanEck Vectors Generic Drugs ETF in Q4 2016 and held it in 1 quarter.
  • Ladenburg Thalmann Financial Services's VanEck Vectors Generic Drugs ETF position peaked at $4K in Q4 2016.
  • 4 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q1 2017.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2017, filed 15 May 2017.